Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing
Optimum, cost-effective, and pragmatic screening for and diagnosis of important health disorders remains a key aspect of clinical care. With this in mind, the American Diabetes Association formally accepted the use of HbA1c as a diagnostic test for type 2 diabetes in January, 2010.1 Although this de...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
Lancet
2016
|
| _version_ | 1797060222131372032 |
|---|---|
| author | Preiss, D Sattar, N |
| author_facet | Preiss, D Sattar, N |
| author_sort | Preiss, D |
| collection | OXFORD |
| description | Optimum, cost-effective, and pragmatic screening for and diagnosis of important health disorders remains a key aspect of clinical care. With this in mind, the American Diabetes Association formally accepted the use of HbA1c as a diagnostic test for type 2 diabetes in January, 2010.1 Although this decision was opposed by some, key organisations accepted use of HbA1c as a diagnostic test. HbA1c was subsequently added to the diagnosis algorithm for type 2 diabetes in the joint European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines2 on the management of diabetes and cardiovascular disease. |
| first_indexed | 2024-03-06T20:14:17Z |
| format | Journal article |
| id | oxford-uuid:2ba042f1-e714-445b-8a2b-98259302f00b |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:14:17Z |
| publishDate | 2016 |
| publisher | Lancet |
| record_format | dspace |
| spelling | oxford-uuid:2ba042f1-e714-445b-8a2b-98259302f00b2022-03-26T12:32:03ZScreening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testingJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2ba042f1-e714-445b-8a2b-98259302f00bSymplectic Elements at OxfordLancet2016Preiss, DSattar, NOptimum, cost-effective, and pragmatic screening for and diagnosis of important health disorders remains a key aspect of clinical care. With this in mind, the American Diabetes Association formally accepted the use of HbA1c as a diagnostic test for type 2 diabetes in January, 2010.1 Although this decision was opposed by some, key organisations accepted use of HbA1c as a diagnostic test. HbA1c was subsequently added to the diagnosis algorithm for type 2 diabetes in the joint European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines2 on the management of diabetes and cardiovascular disease. |
| spellingShingle | Preiss, D Sattar, N Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing |
| title | Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing |
| title_full | Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing |
| title_fullStr | Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing |
| title_full_unstemmed | Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing |
| title_short | Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing |
| title_sort | screening for diabetes in patients with cardiovascular disease hba1c trumps oral glucose tolerance testing |
| work_keys_str_mv | AT preissd screeningfordiabetesinpatientswithcardiovasculardiseasehba1ctrumpsoralglucosetolerancetesting AT sattarn screeningfordiabetesinpatientswithcardiovasculardiseasehba1ctrumpsoralglucosetolerancetesting |